Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trial

Table 1 Plasma markers assessed in the post hoc analysis

Hypoxia-related markers		Signaling pathways		Inflammation		Bone-related markers		Micro-environment/angiogenesis
Marker	Ref.	Marker	Ref.	Marker	Ref.	Marker	Ref.	Marker	Ref.
CA9	[34]	VEGFA-VEGFR2	[14]	CRP	[35]	BSAP	[12]	TIMP-2	[36]
GLUT1	[37]	HGF- c-MET	[7, 10, 16]	IL-6	[38]	SEMA3C	[39]	IL-8	[40, 41]
Clusterin	[42]	FLT3-FLT3L	[18]			Trap5B	[43]	Thrombo-spondin-1	[44]
Caveolin	[45]	IGF1R-IGFI/IGFII	[20, 46, 47]					ANG2-TIE2	[48, 18]
Osteopontin	[49]	AXL-GAS6	[30, 10, 16]
		SCF	[18]

ISSN: 1479-5876